Holen Sie sich die Stockscreener-App
36.00
1.58%
0.56
Handel nachbörslich:
36.00
Schlusskurs vom Vortag:
$35.44
Offen:
$35.51
24-Stunden-Volumen:
2.47M
Relative Volume:
0.66
Marktkapitalisierung:
$15.56B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
15.65
EPS:
2.3
Netto-Cashflow:
$827.02M
1W Leistung:
-0.28%
1M Leistung:
-0.99%
6M Leistung:
+11.49%
1J Leistung:
+29.17%
1-Tages-Spanne:
$35.50
$36.13
1-Wochen-Bereich:
$35.23
$36.36
52-Wochen-Spanne:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.00 | 15.32B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
What indicators show strength in Royalty Pharma plcJuly 2025 Movers & Breakout Confirmation Trade Signals - newser.com
What’s the recovery path for long term holders of Royalty Pharma plcGlobal Markets & AI Enhanced Trading Alerts - newser.com
Callan Family Office LLC Buys Shares of 16,418 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally? - Yahoo Finance
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Why retail investors pile into Royalty Pharma plc stockQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Royalty Pharma plc (RPRX) Stock Analysis: Unveiling a 23.59% Upside Potential in the Biotech Royalty Space - DirectorsTalk Interviews
Is this a good reentry point in Royalty Pharma plcQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
Royalty Pharma PLC $RPRX Shares Sold by Board of the Pension Protection Fund - MarketBeat
Inspire Investing LLC Buys 22,436 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What candlestick patterns are forming on Royalty Pharma plcJuly 2025 Setups & Risk Managed Investment Signals - newser.com
KLP Kapitalforvaltning AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Belpointe Asset Management LLC Purchases New Position in Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025 - TradingView
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan
Custom watchlist performance reports with Royalty Pharma plcPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Royalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss Ratings - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meeting2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - sharewise.com
Why Royalty Pharma plc stock is a must watch in 2025Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Understanding Royalty Pharma plc’s price movementMarket Growth Review & Accurate Technical Buy Alerts - newser.com
A Look at Royalty Pharma’s (RPRX) Valuation Following Imdelltra Royalty Acquisition and Board Enhancement - Sahm
Will Royalty Pharma plc stock see PE expansion2025 Analyst Calls & AI Driven Price Predictions - newser.com
Royalty Pharma collaborates with Biogen for R&D funding - MSN
Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Will Royalty Pharma's (RPRX) Governance Shift Sharpen Its Edge in Life Sciences Investment? - simplywall.st
The Goldman Sachs Group Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com Nigeria
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
Goldman Sachs Starts Royalty Pharma (RPRX) at Buy, PT $42 - StreetInsider
Royalty Pharma appoints Ted Love as lead independent director By Investing.com - Investing.com Nigeria
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):